What is Qsymia? Qsymia is a combination of the appetite suppressant phentermine (the safe half of the diet drug Fen-Phen) and the anti-seizure/migraine medication topiramate.

The other half of Qsymia is the seizure/migraine drug topiramate. Topiramate causes weight loss in several ways, including increasing feelings of fullness, making foods taste less appealing, and ...

Qsymia, the combination diet drug composed of phentermine and topiramate, was approved by the FDA in July of 2012. Now, the results of a study conducted between December 2007 and September 2008 and ...

QSYMIA is the leading non-injectable branded weight loss medication in the U.S. for adults. QSYMIA is a combination of phentermine, a sympathomimetic amine anorectic, and topiramate, indicated in ...

Qsymia is expected be to be available in certified retail pharmacies within 90 days. For more information call (888) 998-4887 or visit www.qsymia.com. Related News.

Findings showed that at the end of the study, treatment with Qsymia resulted in statistically significant reduction in BMI (primary endpoint) compared with placebo (-4.8% with 7.5mg/46mg dose and ...

Qsymia is approved for use in obese adults, those with a body mass index of 30 or greater, and overweight adults, those with BMI of 27 or greater, who have at least one weight-related condition ...

Starting today, the newly FDA-approved diet drug Qsymia is available by prescription. Made by Vivus Inc., the weight-loss pill is approved for obese patients with a body mass index (BMI) of 30 or ...

CAMPBELL, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing ...

Qsymia is approved for use in obese adults, those with a body mass index of 30 or greater, and overweight adults, those with BMI of 27 or greater, who have at least one weight-related condition ...